Alemtuzumab 1 of 4
Our research 2 of 4
Our people 3 of 4
For people with MS 4 of 4
Welcome
Thank you for taking an interest in our work. We hope that you can find what we are looking for, whether you are a colleague scientist, a patient with neurological disease or generally interested. Please do not hesitate to contact us directly.
Featured News
EMA lifts restriction on alemtuzumab use
The EMA has made the sensible decision to lift its previous temporaray restriction and allow alemtuzumab to be used first-line…
EMA announces temporary restriction on alemtuzumab prescribing
The EMA and MHRA are worried about the safety of alemtuzumab and today [12th April 2019] announced a temorary restriciton…
People often experience pyrexia and an urticarial rash within an hour or two of starting an infusion of alemtzumab. Occasionally,…